Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity Nov 6, 2025 08:00AM
Palatin Technologies prices $15.8 million public offering Nov 6, 2025 07:30AM
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering Nov 6, 2025 07:30AM
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim Sep 22, 2025 07:30AM
Palatin Technologies executes 1-for-50 reverse stock split Aug 8, 2025 04:00PM


Aug 8, 2025 04:00PM Palatin Announces 1-for-50 Reverse Stock Split
Jul 15, 2025 07:30AM Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
May 14, 2025 07:30AM Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
May 9, 2025 07:30AM Internet Patents (PTNT) vPresents Promising Preclinical Data on Melanocortin Agonists for Retinopathy
May 9, 2025 07:30AM Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
May 8, 2025 10:19PM Palatin Technologies Announces Closing of Reduced Public Offering
May 8, 2025 04:39PM Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025